Christopher A. Posner
Net Worth
Last updated:
What is Christopher A. Posner net worth?
The estimated net worth of Mr. Christopher A. Posner is at least $1,661,341 as of 2 May 2024. He owns shares worth $953,488 as insider, has earned $420,353 from insider trading and has received compensation worth at least $287,500 in Cara Therapeutics, Inc..
What is the salary of Christopher A. Posner?
Mr. Christopher A. Posner salary is $57,500 per year as Pres, Chief Executive Officer & Director in Cara Therapeutics, Inc..
How old is Christopher A. Posner?
Mr. Christopher A. Posner is 55 years old, born in 1970.
What stocks does Christopher A. Posner currently own?
As insider, Mr. Christopher A. Posner owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Cara Therapeutics, Inc. (CARA) | Pres, Chief Executive Officer & Director | 176,585 | $5.4 | $953,488 |
What does Cara Therapeutics, Inc. do?
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Christopher A. Posner insider trading
Cara Therapeutics, Inc.
Mr. Christopher A. Posner has made 13 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 3,936 units of CARA stock worth $2,952 on 2 May 2024.
The largest trade he's ever made was exercising 35,575 units of CARA stock on 8 Feb 2024. As of 2 May 2024 he still owns at least 176,585 units of CARA stock.
Cara Therapeutics key executives
Cara Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Derek T. Chalmers D.Sc., Ph.D. (61) Co-Founder & Senior Advisor
- Dr. Frédérique Menzaghi (59) Chief Scientific Officer and Senior Vice President of R&D
- Dr. Joana Goncalves (51) Chief Medical Officer
- Mr. Christopher A. Posner (55) Pres, Chief Executive Officer & Director
- Mr. Richard Makara (54) Vice President, Head of Accounting, Controller & Principal Accounting Officer
- Mr. Scott M. Terrillion (62) Chief Compliance Officer, Gen. Counsel & Corporation Sec.
- Mr. Thomas Charles Reilly (53) Chief Financial Officer